Skip to main content
Premium Trial:

Request an Annual Quote

Matrix, BioVision Team Up to Develop Proteomics Software

NEW YORK, Dec 6 – Matrix Science of London and BioVision of Hannover, Germany said Wednesday that they would jointly develop a bioinformatics tool designed to analyze and process molecular data generated by any brand of mass spectrometer.

“If a lab has different mass spectrometers from different manufacturers there is no software that allows them to get consistent results. Lots of them do the job of peak detection and data processing quite poorly,” said David Creasy, director of Matrix Science. “We’ve got a lot of experience with the different types of data from different manufacturers.”

Matrix’s first commercially available product, Mascot, offers a search engine that uses mass spectrometry data to identify proteins from primary sequence databases.

Creasy said BioVision would provide testing and feedback for the new software, which will be developed by Matrix, a small start-up with three employees. BioVision specializes in identifying previously unknown human peptides and determining how they relate to disease.

Creasy said he expects the jointly produced tool to be released for commercialization in the middle of 2001.

The Imperial Cancer Research Fund is also serves as a consultant to Matrix.

Creasy noted that several major pharmaceutical companies, such as Glaxo Wellcome, SmithKline Beecham, and Pharmacia, have purchased the company’s Mascot product for use in house. For researchers willing to work on-line, the software is available free at www.matrixscience.com .

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.